The vaccine, developed with the Indian Council of Medical Research (ICMR), is being evaluated in a separate 25,800 person trial, which started in November. Bharat Biotech said on Friday 13,000 people participating in the late-stage trial had been given the second dose. The interim data published in the journal included three different vaccine formulations and a placebo group among 375 adults. Two formulations of the vaccine, called COVAXIN, have been selected for more advanced stages of testing and further efficacy trials are warranted, the report said. COVAXIN is an inactivated vaccine that introduces dead virus into the body to trigger an immune response.

Source: bd News24 January 23, 2021 10:41 UTC